

## Clinical Criteria

<b>Subject:</b>	Amondys 45 (casimersen) – NY Medicaid		
<b>Document #:</b>	ING-CC-0189 - NY	<b>Publish Date:</b>	04/01/2022
<b>Status:</b>	New	<b>Last Review Date:</b>	02/25/2022

### Table of contents

<a href="#">Overview</a>	<a href="#">Coding</a>	<a href="#">References</a>
<a href="#">Clinical criteria</a>	<a href="#">Document history</a>	

### Overview

This document addresses the use of Amondys 45 (casimersen) in the treatment of Duchenne muscular dystrophy (DMD) with a mutation amenable to exon 45 skipping. DMD is a genetic disorder characterized by decrease in muscle mass over time, including progressive damage and weakness of facial, limb, respiratory and heart muscles. In DMD patients, dystrophin, a protein that is present in skeletal and heart muscles allowing the muscles to function properly, is either absent or found in very small amounts. In theory, exon 45 skipping allows for the creation of a shorter-than-normal, but partially functional, dystrophin protein in patients with a specific type of DMD mutation.

Per the Amondys 45 package insert, Amondys 45 was approved by the FDA under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with Amondys 45. Continued approval may be contingent upon verification of a clinical benefit in confirmatory trials. The label indicates there may be a risk of kidney toxicity with Amondys 45. Because of this, kidney function should be monitored. However, creatinine may not be a reliable indicator of renal function in DMD patients.

The ESSENCE trial is a phase 3 trial that includes both casimersen and golodirsen. Inclusion criteria for the ESSENCE trial (NCT02500381) are found on [clinicaltrials.gov](https://clinicaltrials.gov) and are listed as follows:

- Males age 7-13
- Genotypically confirmed DMD, with genetic deletion amenable to exon 45 or exon 53 skipping
- Stable dose of oral corticosteroids for at least 24 weeks
- Intact right and left biceps or 2 alternative upper muscle groups
- Mean 6MWT greater than or equal 300 meters and less than or equal to 450 meters
- Stable pulmonary function: forced vital capacity (FVC) equal to or greater than 50% predicted

Estimated primary completion date for ESSENCE is May 2022 with estimated study completion in May 2023. An additional open label trial is being done (NCT03532542) that requires individuals have completed a clinical trial evaluating either casimersen or golodirsen, per protocol, with an estimated completion date of August 2026. Currently, there are no published data or trial results available for casimersen.

Prior to starting Amondys 45, serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured. Amondys 45 is administered via a once weekly IV infusion at a dose of 30 mg/kg over 35-60 minutes.

### <https://providerpublic.mycbswny.com>

Amerigroup Partnership Plan, LLC provides management services for Highmark Blue Cross Blue Shield of Western New York's managed Medicaid. Amerigroup Partnership Plan, LLC brinda servicios administrativos para Medicaid administrado de Highmark Blue Cross Blue Shield of Western New York.

Highmark Blue Cross Blue Shield of Western New York is a trade name of Highmark Western and Northeastern New York Inc., an independent licensee of the Blue Cross Blue Shield Association. Highmark Blue Cross Blue Shield of Western New York es un nombre comercial de Highmark Western y Northeastern New York Inc., un licenciario independiente de Blue Cross Blue Shield Association.

## Clinical criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

### Amondys 45 (casimersen)

Initial requests for Amondys 45 (casimersen) may be approved if the following criteria are met:

- I. Individual has a confirmed diagnosis of Duchenne muscular dystrophy (DMD); **AND**
- II. Documentation is provided that individual has a genetic mutation that is amenable to exon 45 skipping; **AND**
- III. Individual is age 7-13 years (NCT02500381); **AND**
- IV. Individual has been on a stable dose of oral corticosteroids (NCT02500381); **AND**
- V. Documentation indicates kidney function testing prior to starting therapy; **AND**
- VI. Individual will not use with any other exon skipping agents for DMD (including but not limited to Exondys 51, Vyondys 53).

Continuation of therapy with Amondys 45 (casimersen) may be approved if the following criterion are met:

- I. Criteria above were met at initiation of therapy

**Approval Duration:** 6 months

Requests for Amondys 45 (casimersen) may not be approved when the criteria above are not met and for all other indications.

## Quantity Limits

### Amondys 45 (casimersen) Quantity Limits

Drug	Limit
Amondys 45 (casimersen)	30 mg/kg once weekly

## Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

### HCPCS

**J1426** Injection, casimersen, 10 mg [Amondys 45]

### ICD-10 Diagnosis

**G71.00-G71.09** Muscular dystrophy

## Document history

Reviewed: 02/25/2022

Document History:

- 02/25/2022 – New York specific policy created based on guidance released from NYSDOH. Effective 04/01/2022.

- 08/20/2021 – Annual Review: No changes. Coding review: No changes. Effective 10/1/2021 Added J1426. Deleted 9/30/2021 J3490, J3590, C9075. Delete all diagnoses pend.
- 03/01/2021 – Select review: Added new clinical criteria document with clinical criteria based on inclusion parameters of clinical trial NCT02500381; added quantity limit based on label. Coding Reviewed: Added HCPCS J3490, J3590, C9399. All diagnosis pend. Effective 7/1/21 Added C9075. Removed HCPCS C9399. Added ICD-10-CM G71.00-G71.09.

## References

1. Kole R, Krieg AM. Exon skipping therapy for Duchenne muscular dystrophy. *Ad Drug Del Rev.* 2015; 87:140-107.
2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available at: <https://clinicaltrials.gov/ct2/home> Accessed on January 28, 2021.
3. Amondys 45 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; 2021.
4. "New York State Medicaid Update – January 2022 Volume 38 – Number 1". New York State Department of Health, 01 Feb. 2022, [https://health.ny.gov/health\\_care/medicaid/program/update/2022/no01\\_2022-01.htm](https://health.ny.gov/health_care/medicaid/program/update/2022/no01_2022-01.htm)

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association